lupus.bmj4d
Which outcome measures in SLE clinical trials best reflect medical judgment?
Objectives To compare two measures of systemic lupus erythematosus (SLE) response: the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and the Systemic Lupus ...
lupus.bmj12d
Adverse pregnancy outcomes and subsequent risk of cardiovascular disease in women with systemic lupus erythematosus
4 Department of Preventive Medicine, Feinberg School of Medicine, Chicago, Illinois, USA Background/objective Patients with systemic lupus erythematosus (SLE) are at increased risk for adverse ...
lupus.bmj13d
Predictors of refractory risk in systemic lupus erythematosus-related thrombocytopenia: a dual-centre retrospective study
Objectives Based on clinical and laboratory indicators, this study aimed to establish a multiparametric nomogram to assess the risk of refractory cases of SLE-related thrombocytopenia (SLE-related TP) ...
lupus.bmj9d
Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE
Objective To assess the efficacy of anifrolumab, a type-1 interferon receptor subunit-1 monoclonal antibody, in treating refractory cutaneous lupus erythematosus (CLE) and lupus non-specific ...
lupus.bmj13d
426 Renal activity and damage incur highest medical costs among filipino patients with systemic lupus erythematosus
Background and aims Systemic lupus erythematosus (SLE) predominantly affects individuals at peak age of productivity, and medical costs negatively impact on personal, family and community resources.
lupus.bmj6d
The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness
Background Previous reports indicate that treating patients with lupus (SLE) at or close to the time of diagnosis successfully without using any, or minimal, corticosteroids by using B-cell depletion ...
lupus.bmj13d
Dancing with disorder: chorea – an unusual and neglected manifestation of antiphospholipid syndrome
Objectives Chorea, characterised by involuntary, irregular movements, is a rare neurological manifestation of antiphospholipid syndrome (APS). The specific clinical features remain unclear. This study ...
lupus.bmj7d
Patients with overlap autoimmune disease differ from those with ‘pure’ disease
Objective To determine frequency, demographic and treatment characteristics of patients with an overlapping second autoimmune illness (2nd AI). Methods We analysed two cohorts containing 897 patients ...
lupus.bmj1mon
05 Management of lupus in low-middle income countries
Systemic lupus erythematosus (SLE) predominantly affects young individuals with potential to be productive members of society. SLE also significantly increases healthcare utilization with higher ...
lupus.bmj1mon
22 Lupus in my lifetime – as tears go by
With its first description published in 1976 the bimodal mortality pattern in systemic lupus erythematosus (SLE) described early mortality as usually being due to lupus disease itself or infection, ...
lupus.bmj1mon
11 Meet the editor
In the past decade, the world of publishing has undergone rapid changes with the proliferation of online journals and the advances of the open access movement. Consequently, the roles of authors and ...
lupus.bmj1mon
07 The matter of the debate: this house believes that we should (follow the EMA guidelines and) avoid using DOACs in APS and SLE/APS (Against)
Direct oral anticoagulants (DOACs) are the standard of care for anticoagulation following a first episode of venous thromboembolism (VTE) in the general population, however, special considerations ...